Generation of Tumor Cells Expressing Firefly Luciferase (fLuc) to Evaluate the Effectiveness of CAR in a Murine Model
Immunotherapy has been showed as a promisor treatment, in special for hematological diseases. Chimeric antigen receptor T cells (CARs) which are showing satisfactory results in early-phase cancer clinical trials can be highlighted. However, preclinical models are critical steps prior to clinical trial. In this way, a well-established preclinical model is an important key in order to confirm the proof of principle. For this purpose, in this chapter will be pointed the methods to generate tumor cells expressing firefly Luciferase. In turn, these modified cells will be used to create a subcutaneous and a systemic murine model of Burkitt’s lymphoma in order to evaluate the effectiveness of CAR-T.
Key wordsPreclinical model Subcutaneous model Systemic model Luciferase Bioluminescence imaging CAR-T
This work was supported by São Paulo Research Foundation—FAPESP 17/09491-8, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), CTC Center for Cell-based Therapies (FAPESP 2013/08135-2), and National Institute of Science and Technology in Stem Cell and Cell Therapy (CNPq 573754-2008-0 and FAPESP 2008/578773). The authors also acknowledge financial support from Secretaria Executiva do Ministério da Saúde (SE/MS), Departamento de Economia da Saúde, Investimentos e Desenvolvimento (DESID/SE), Programa Nacional de Apoio à Atenção Oncológica (PRONON) Process 25000.189625/2016-16.
- 4.Cosette J, Ben Abdelwahed R, Donnou-Triffault S et al (2016) Bioluminescence-based tumor quantification method for monitoring tumor progression and treatment effects in mouse lymphoma models. J Vis Exp 113. https://doi.org/10.3791/53609